Plasma metabolomic signatures of all and cause-specific cancers: a multi-platform population-based study.

ABSTRACT:

Introduction

Early diagnosis of cancer is essential for improving patient outcomes. Metabolomics analysis has shown promise in detecting cancer and distinguishing its metastatic burdens in previous studies.

Objectives

We hypothesized that metabolomics data can differentiate between people with and without cancer at a population level, uncovering new biomarkers and deepening our understanding of cancer metabolism.

Methods

A total of 1,386 metabolites were measured by two commonly used metabolomics platforms: Nightingale and Metabolon, in baseline plasma samples from participants in the population-based Rotterdam Study, with sample sizes of 2,538 and 5,057, respectively. Logistic regression and competing risk Cox proportional hazards models were employed to examine asso

SUBMITTER: Shuai Y 

PROVIDER: S-EPMC12923424 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature